Transanal treatment of rectal cancer by soft platform
Editorial

Transanal treatment of rectal cancer by soft platform

Niu Zhang, Mahir Gachabayov, Roberto Bergamaschi

Section of Colorectal Surgery, Department of Surgery, Westchester Medical Center, New York Medical College, Valhalla, NY, USA

Correspondence to: Roberto Bergamaschi, MD, PhD, FRCS, FASCRS, FACS. Section of Colorectal Surgery, Department of Surgery, Westchester Medical Center, New York Medical College, Taylor Pavilion, Suite D-365, 100 Woods Road, Valhalla, NY 10595, USA. Email: rcmbergamaschi@gmail.com.

Received: 03 May 2018; Accepted: 15 May 2018; Published: 28 May 2018.

doi: 10.21037/ales.2018.05.04


The first approach to the management of rectal cancer was transanal, and it predated the era of laparotomy (1). Over a century passed before a transanal, this time endoscopic approach would be grabbing the headlines (2). This endoscopic approach consisted of a rigid platform, which required a shallow learning curve and a capital budget purchase. The latter factor most likely limited its popularization in the United States given the financial accountability of private institutions requesting sufficient patient volume. Hence, it is not surprising that an American surgeon developed and implemented the concept of soft platform named transanal minimally invasive surgery (TAMIS) (3).

The procedure is performed by inserting a disposable FDA-approved single-incision port in the anal canal with the patient prone or supine depending on the location of the lesion in the rectum. A pneumorectum is created insufflating CO2, and laparoscopic instruments are inserted. A retrospective cohort study including 50 patients undergoing TAMIS reported a 4.3% rate of positive margins for malignant tumors and 8% rate for benign tumors (4). Notwithstanding the opportunities for better visualization, simpler technique and less expensive instrumentation, TAMIS is not flawless. Its limitations include: restricted working angles within the confined space of the rectal lumen, and external torque in attempt to compensate for the lack of instruments’ articulation (5).

It should not be surprising that the above-mentioned limitations of laparoscopic instruments created an opportunity for a robotic transanal approach. One of the goals of a robotic soft platform would be to facilitate the suture closure of an anterior rectal wall defect (6). Clearly, the 360º range of motion of the robotic instruments in the rectal lumen is the key advantage. The reassignment of the robotic arms from left to right and vice versa after instrument crossing and the 3D high-definition visualization allow for instrument manipulation similar to open surgery. Cadaveric studies have shown robotic soft platform to be a precise method for local excision of ‘pseudolesions’ allowing surgeons unprecedented control of the operative field (5,7,8). The only available clinical data consist of few case reports and one multicenter study including 16 patients only (5,7-16). The latter study, however, reported positive margins in 2 of 16 cases (13%) (16). Alongside with advantages, a robotic soft platform has limitations, such as learning curve and cost.

The main focus of an editorial on transanal approach to rectal tumors should not be solely the surgical technique involved but rather the appropriate applications to clinical practice. To that end, the naïve reader should take with a grain of salt “randomized” studies on transanal rigid platform for rectal cancer claiming oncologic outcomes similar to total mesorectal excision (TME) (17). In fact, reliable data suggest that transanal excision may result in inferior oncologic outcomes including higher risk of cancer-related death (18). Therefore, the proper indication for transanal excision by soft platform is benign tumors of the rectum. With regard to differences between rigid and soft platform, it is the authors’ opinion that what matters is not the technical aspects but rather the type of healthcare system. As a matter of fact, a rigid platform would be purchased with taxpayers’ money in a government run healthcare. In conclusion, transanal excision of rectal cancer (regardless of the platform being rigid or soft) should be restricted to patients with prohibitive comorbidities precluding TME or offered for palliation.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Volkmann R. Sammlung Klinischer Vortrage im Verbindung mit deutschen Klinikern. Chirurgie 1874;29:1113-27.
  2. Buess G, Theiss R, Hutterer F, et al. Transanal endoscopic surgery of the rectum - testing a new method in animal experiments. Leber Magen Darm 1983;13:73-7. [PubMed]
  3. Atallah S, Albert M, Larach S. Transanal minimally invasive surgery: a giant leap forward. Surg Endosc 2010;24:2200-5. [Crossref] [PubMed]
  4. Albert M, Atallah S, deBeche-Adams TC, et al. Transanal Minimally Invasive Surgery (TAMIS) for local excision of benign neoplasms and early-stage rectal cancer: Efficacy and outcomes in the first 50 patients. Dis Colon Rectum 2013;56:301-7. [Crossref] [PubMed]
  5. Atallah S, Albert M, deBeche-Adams TC, et al. Robotic transanal minimally invasive surgery in a cadaveric model. Tech Coloproctol 2011;15:461-4. [Crossref] [PubMed]
  6. Popa D, Connolly TM, Barbon C, et al. Design defects can close a study. Colorectal Dis 2015;17:1121-2. [Crossref] [PubMed]
  7. Hompes R, Rauh SM, Hagen ME, et al. Preclinical cadaveric study of transanal endoscopic da Vinci surgery. Br J Surg 2012;99:1144-8. [Crossref] [PubMed]
  8. Marks J, Ng S, Mak T. Robotic transanal surgery (RTAS) with utilization of a next-generation single-port system: a cadaveric feasibility study. Tech Coloproctol 2017;21:541-5. [Crossref] [PubMed]
  9. Atallah S, Quinteros F, Martin-Perez B, et al. Robotic transanal surgery for local excision of rectal neoplasms. J Robot Surg 2014;8:193-4. [Crossref] [PubMed]
  10. Atallah S, Parra-Davila E, deBeche-Adams T, et al. Excision of a rectal neoplasm using robotic transanal surgery (RTS): a description of the technique. Tech Coloproctol 2012;16:389-92. [Crossref] [PubMed]
  11. Buchs NC, Pugin F, Volonte F, et al. Robotic transanal endoscopic microsurgery: technical details for the lateral approach. Dis Colon Rectum 2013;56:1194-8. [Crossref] [PubMed]
  12. Erenler I, Aytac E, Bilgin IA, et al. Robotic transanal minimally invasive surgery (R-TAMIS) with the da Vinci Xi system – a video vignette. Colorectal Dis 2017;19:401. [Crossref] [PubMed]
  13. Harr JN, Obias V. Robotic-assisted transanal excision of a large rectal mass – a video vignette. Colorectal Dis 2016;18:107-8. [Crossref] [PubMed]
  14. Laird R, Obias VJ. Robotic transanal fistula repair – a video vignette. Colorectal Dis 2015;17:90. [Crossref] [PubMed]
  15. Stack ME, Umanskiy K. Robotic-assisted transanal repair of a rectovaginal fistula. J Gastrointest Surg 2016;20:2106. [Crossref] [PubMed]
  16. Hompes R, Rauh SM, Ris F, et al. Robotic transanal minimally invasive surgery for local excision of rectal neoplasms. Br J Surg 2014;101:578-81. [Crossref] [PubMed]
  17. Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg 2012;99:1211-8. [Crossref] [PubMed]
  18. Nash GM, Weiser MR, Guillem JG, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009;52:577-82. [Crossref] [PubMed]
doi: 10.21037/ales.2018.05.04
Cite this article as: Zhang N, Gachabayov M, Bergamaschi R. Transanal treatment of rectal cancer by soft platform. Ann Laparosc Endosc Surg 2018;3:49.